Kymera Therapeutics
NasdaqGM:KYMR Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
AN
Consensus Narrative from 19 Analysts
Advancing STAT6 And TYK2 Clinical Programs Will Open New Therapeutic Markets
Key Takeaways Advancing clinical programs and strategic partnerships could increase market share and positively impact future revenue and earnings. Solid cash runway supports focused R&D investments, potentially boosting long-term growth without immediate financing pressures.
View narrativeUS$57.95
FV
45.1% undervalued intrinsic discount20.59%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
4 days ago author updated this narrative